Notification That Annual Report Will Be Submitted Late (nt 10-k)
April 02 2018 - 11:31AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
Commission
File Number
000-22179
(Check
One):
[X] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10D
[
] Form N-SAR [ ] Form N-CSR
For
Period Ended:
December 31, 2017
[ ]
|
Transition Report on Form
10-K
|
[ ]
|
Transition Report on Form 20-F
|
[ ]
|
Transition Report on
Form 11-K
|
[ ]
|
Transition Report on Form 10-Q
|
[ ]
|
Transition Report on Form N-SAR
|
For
the Transition Period Ended: ___________________
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If the notification relates
to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________________
|
PART
I
REGISTRANT INFORMATION
Full Name of Registrant:
|
Guided Therapeutics, Inc.
|
|
|
|
|
Address of Principal Executive
|
|
|
Office (
Street and number
):
|
5835 Peachtree Corners East, Suite D
|
|
|
|
|
City, State and Zip Code:
|
Norcross, Georgia 30092
|
|
PART
II
RULES
12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
|
(a)
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or
expense;
|
|
|
[X]
|
(b) The subject
annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or Form N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following
the prescribed due date; and
|
|
|
|
(c) The accountant's
statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR or the transition report or portion thereof,
could not be filed within the prescribed time period.
The
registrant’s annual report on Form 10-K could not be filed within the prescribed time period. During the annual period ended
December 31, 2017 (The registrant also late filed its quarterly 10-Q reports in the first, second and third quarter of 2017),
the registrant continued to experience considerable financial constraints. These financial constraints have postponed the ability
of the registrant’s auditors from auditing the Form 10-K and in starting the Financial review process and thus resulted
in delays in the preparation and presentation of financial information. These delays contributed to the registrant’s inability
to process and review the financial information required to file the quarterly report on Form 10-K by the date required without
incurring undue hardship and expense.
The
registrant expects to file its Form 10-K within the permitted extension period.
PART
IV
OTHER
INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification
|
|
Gene
S. Cartwright
|
|
(770)
|
|
242-8723
|
(Name)
|
|
(Area Code)
|
|
(Telephone Number)
|
|
|
|
|
|
|
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file
such report(s) been filed? If answer is no, identify report(s).
Yes
[X ] No [ ]
(3)
Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
Yes
[ ] No [X ]
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
Guided
Therapeutics, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Date:
April 2, 2018
|
By:
/s/
Gene S. Cartwright
|
|
Gene
S. Cartwright
President
and Chief Executive Officer
|
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guided Therapeutics (QB) (USOTC:GTHP)
Historical Stock Chart
From Sep 2023 to Sep 2024